Your browser is no longer supported. Please, upgrade your browser.
Mirum Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-5.41 Insider Own0.60% Shs Outstand30.27M Perf Week-2.83%
Market Cap500.50M Forward P/E- EPS next Y-3.68 Insider Trans-49.17% Shs Float27.79M Perf Month-13.26%
Income-153.10M PEG- EPS next Q-1.73 Inst Own78.80% Short Float1.72% Perf Quarter1.48%
Sales11.00M P/S45.50 EPS this Y-79.10% Inst Trans-0.18% Short Ratio2.54 Perf Half Y-11.54%
Book/sh3.16 P/B5.22 EPS next Y39.80% ROA-71.80% Target Price- Perf Year-14.39%
Cash/sh7.37 P/C2.24 EPS next 5Y- ROE-117.40% 52W Range13.85 - 26.31 Perf YTD-5.61%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-37.36% Beta-
Dividend %- Quick Ratio7.90 Sales past 5Y- Gross Margin- 52W Low18.99% ATR1.06
Employees120 Current Ratio7.90 Sales Q/Q- Oper. Margin- RSI (14)41.98 Volatility3.80% 6.88%
OptionableYes Debt/Eq0.00 EPS Q/Q-55.90% Profit Margin- Rel Volume0.60 Prev Close16.53
ShortableYes LT Debt/Eq0.00 EarningsAug 05 AMC Payout- Avg Volume189.01K Price16.48
Recom1.40 SMA20-8.32% SMA50-2.34% SMA200-7.01% Volume112,802 Change-0.30%
Sep-20-21Initiated JP Morgan Overweight $30
Aug-07-20Upgrade Raymond James Outperform → Strong Buy $28 → $48
Aug-03-20Initiated H.C. Wainwright Buy $52
Jul-31-20Initiated Piper Sandler Overweight $77
Jun-25-20Initiated Robert W. Baird Outperform $30
Aug-12-19Initiated ROTH Capital Buy $33
Aug-12-19Initiated Raymond James Outperform $28
Aug-12-19Initiated Guggenheim Buy $18
Aug-12-19Initiated Evercore ISI Outperform
Aug-12-19Initiated Citigroup Buy $21
Sep-29-21 05:45PM  
Sep-22-21 08:55AM  
Sep-21-21 11:00AM  
Sep-13-21 06:45AM  
Sep-10-21 05:30PM  
Sep-02-21 05:30PM  
Aug-26-21 08:53AM  
Aug-19-21 05:30PM  
Aug-10-21 07:00PM  
Aug-05-21 06:35PM  
Jul-29-21 04:00PM  
Jul-27-21 06:59AM  
Jul-26-21 08:00PM  
Jul-12-21 06:00PM  
Jun-24-21 04:05PM  
Jun-23-21 09:00AM  
Jun-16-21 09:00AM  
Jun-10-21 05:30PM  
Jun-07-21 09:00AM  
Jun-03-21 10:10AM  
May-26-21 09:00AM  
May-12-21 04:47AM  
May-10-21 09:00PM  
May-06-21 07:50PM  
Apr-29-21 04:05PM  
Apr-26-21 09:00AM  
Apr-12-21 05:30PM  
Mar-29-21 09:00AM  
Mar-13-21 03:39AM  
Mar-10-21 06:00PM  
Mar-09-21 05:25PM  
Feb-22-21 09:00AM  
Feb-10-21 05:30PM  
Feb-08-21 10:12AM  
Feb-01-21 09:00AM  
Jan-24-21 09:00AM  
Jan-14-21 09:00AM  
Jan-12-21 09:00AM  
Jan-08-21 06:17PM  
Jan-04-21 08:30AM  
Dec-30-20 02:45AM  
Dec-22-20 08:55AM  
Dec-14-20 09:00PM  
Dec-10-20 10:33PM  
Dec-09-20 09:00AM  
Dec-07-20 09:00AM  
Nov-30-20 08:30AM  
Nov-23-20 09:30AM  
Nov-15-20 06:00PM  
Nov-13-20 08:10AM  
Nov-12-20 09:00AM  
Nov-10-20 07:00PM  
Nov-05-20 08:30AM  
Nov-02-20 08:30AM  
Oct-26-20 08:30AM  
Oct-15-20 08:55AM  
Oct-14-20 10:29AM  
Oct-13-20 04:05PM  
Sep-11-20 04:30PM  
Sep-01-20 09:00AM  
Aug-29-20 08:45AM  
Aug-11-20 05:30PM  
Aug-07-20 04:05PM  
Aug-06-20 04:05PM  
Jul-10-20 05:00PM  
Jun-22-20 02:06PM  
Jun-11-20 04:10PM  
Jun-02-20 08:30AM  
May-29-20 10:05AM  
May-11-20 05:01PM  
May-07-20 04:05PM  
Apr-28-20 04:19PM  
Mar-12-20 04:02PM  
Feb-18-20 04:01PM  
Jan-16-20 09:00AM  
Jan-14-20 09:00AM  
Jan-08-20 08:15PM  
Dec-24-19 10:40AM  
Dec-17-19 07:56AM  
Dec-16-19 08:00AM  
Dec-13-19 04:28PM  
Nov-25-19 08:30AM  
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's lead product candidate is Maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It is also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. The company was incorporated in 2018 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Longpre LaraChief Development OfficerOct 01Sale19.2696118,50584,245Oct 01 08:00 PM
Vig PamelaChief Scientific OfficerOct 01Sale19.261,36426,2659,667Oct 01 08:00 PM
Peetz ChristopherPresident and CEOOct 01Sale19.263,67270,70821,027Oct 01 08:00 PM
Tucker Edwin JonathanChief Medical OfficerOct 01Sale19.261,36426,26545,768Oct 01 08:00 PM
Radovich PeterChief Operating OfficerOct 01Sale19.261,36426,26511,273Oct 01 08:00 PM
Clements IanChief Financial OfficerOct 01Sale19.261,57430,30916,653Oct 01 08:00 PM
Flynn James E10% OwnerJul 09Sale15.8199,3251,570,3280Jul 13 12:06 PM
Flynn James E10% OwnerJul 07Sale15.876,837108,49699,325Jul 07 06:48 PM
Flynn James E10% OwnerJul 06Sale16.2049,239797,426106,162Jul 07 06:48 PM
Flynn James E10% OwnerJul 02Sale17.0110,599180,300155,401Jul 07 06:48 PM
Tucker Edwin JonathanChief Medical OfficerMar 05Option Exercise7.701,0828,33137,524Mar 08 06:40 PM
Tucker Edwin JonathanChief Medical OfficerDec 28Option Exercise7.704,16732,08636,442Dec 29 04:24 PM
Clements IanChief Financial OfficerDec 23Buy18.612,47045,9757,841Dec 28 04:12 PM
Peetz ChristopherPresident and CEODec 23Buy18.705,00093,480201,570Dec 28 04:06 PM
Tucker Edwin JonathanChief Medical OfficerOct 30Option Exercise7.7025,000192,50031,000Nov 03 05:09 PM